ResMed Inc (NYSE:RMD) target price raised to $64.00, issued a report today by JP Morgan
- Updated: October 4, 2016
Yesterday ResMed Inc (NYSE:RMD) traded 0.72% higher at $64.15. The company’s 50-day moving average is $66.37 and its 200-day moving average is $62.35. The last closing price is up 3.91% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 195,289 shares of ResMed Inc exchanged hands, down from an avg. volume of 964,044
ResMed Inc (NYSE:RMD) had its target price raised to $64.00 by JP Morgan in a report released 10/04/2016. The new target price indicates consistent performance relative to the company's last closing price.
With a total market value of $0, ResMed Inc has price-earnings ratio of 26.02 with a one year low of $50.77 and a one year high of $70.90 .
A total of 11 equity analysts have released a ratings update on RMD. One equity analyst rating the company a strong buy, four equity analysts rating the company a buy, eight equity analysts rating the company a hold, two equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $59.06.
Brief Synopsis About ResMed Inc (NYSE:RMD)
ResMed Inc. is a holding company. The Company, through its subsidiaries, designs, manufactures and markets equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. The Company develops a range of products for sleep-disordered breathing and other respiratory disorders, including airdevices, informatics solutions, diagnostic products, mask systems, headgear and other accessories. The Company owns interest in Inova Labs Inc., a medical device company specializing in the development and commercialization of oxygen therapy products. The Company holds interest in Brightree LLC, a provider of business management and clinical software applications for the post-acute care industry. The Company's manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.